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Summary
Objectives:  This  study  aimed  to  determine  the  prevalence  of  extended  spectrum  of
beta  lactamases  (ESBLs),  to  compare  different  phenotypic  methods  for  ESBL  con-
ﬁrmation  and  to  evaluate  the  antibiotic  resistance  patterns  among  ESBL-producing
urinary  Escherichia  coli.
Methods:  Urinary  E.  coli  isolates  that  were  resistant  to  at  least  one  of  the  three  indi-
cator  cephalosporins  (cefotaxime,  cefpodoxime  and  ceftazidime)  were  tested  for
ESBL  production  using  the  double  disc  synergy  test  (DDST),  the  inhibitory  potentiated
disc  diffusion  (IPDD)  test  and  the  quantitative  E-strip  method.
Result:  Of  the  163  E.  coli  strains  isolated,  80  (49%)  were  resistant  to  at  least  one
of  the  three  cephalosporins,  and  38  (47.5%)  tested  positive  for  ESBLs  by  the  IPDD
test  and  the  E-strip  test.  However,  only15  (18.7%)  strains  tested  positive  by  the
DDST.  Among  the  third-generation  cephalosporins,  cefpodoxime  (46.1%)  was  the  best
screening  indicator,  followed  by  ceftazidime  (43%)  and  cefotaxime  (39.9%).  Most  of
the  ESBL  producers  (97.3%)  were  resistant  to  three  or  more  drugs,  compared  with
51.2%  of  non-ESBL  producers.
Conclusion:  Compared  with  the  DDST,  the  IPDD  and  E-strip  tests  appear  to  be  prefer-
able  methods  for  detecting  ESBLs,  with  better  sensitivity  (100%)  and  speciﬁcilty
(97.6%)  and  positive  predictive  values  (97.3%).  ESBL  producers  showed  signiﬁcantly
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(p  <  0.05)  higher  resistance  to  tobramycin,  co-amoxyclav  and  amikacin  than  did  non-
ESBL  producers.
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Disc susceptibility test to screen for ESBLs
All  isolates  were  screened  for  ESBL  produc-©  2012  King  Saud  Bin  Ab
Ltd.  All  rights  reserved.
ntroduction
espite  the  widespread  availability  of  antibi-
tics, urinary  tract  infections  (UTIs)  remain  the
ost common  bacterial  infections  in  humans  [1].
mong the  wide  array  of  available  antibiotics,
-lactams are  the  most  varied  and  most  widely
sed agents,  accounting  for  over  50%  of  all  sys-
emic antibiotics  in  use  [2].  The  most  common
ause of  bacterial  resistance  against  -lactam
ntibiotics is  the  production  of  -lactamases
3]. Many  of  the  second-  and  third-generation
ephalosporins  were  speciﬁcally  designed  to  resist
he hydrolytic  action  of  major  -lactamases.
owever,  the  evolution  of  extended-spectrum  -
actamases  (ESBLs)  has  added  another  weapon  to
he arsenal  of  these  enzymes.  ESBLs  are  commonly
roduced by  many  members  of  Enterobacteri-
ceae,  especially  Escherichia  coli  and  Klebsiella
neumoniae. These  organisms  efﬁciently  hydrolyze
xyimino-cephalosporins,  conferring  resistance  to
hird-generation  cephalosporins  and  monobactams
4].
The detection  of  ESBLs  is  a  challenge  for  routine
linical microbiology  laboratories  in  resource-
imited settings,  and  the  detection  of  a  decrease
n susceptibility  to  oxyimino-cephalosporins  is  not
ufﬁciently  sensitive  to  detect  all  ESBL-producing
trains. The  guidelines  developed  by  the  Comite  de
’Antibiogramme  de  la  Societe  Francaise  de  Micro-
iologie  [5]  (CA-FSM)  and  the  European  Committee
n Antimicrobial  Susceptibility  Testing  [6]  (EUCAST)
ecommend  screening  for  ESBL-producing  isolates
ased on  decreased  susceptibility  to  extended-
pectrum cephalosporins  in  primary  antibiotic  disc
iffusion tests  along  with  one  additional  conﬁrma-
ory test.  However,  the  most  sensitive  method  for
he phenotypic  detection  of  ESBL  remains  unknown
7]. Existing  phenotypic  methods  of  ESBL  detection
nclude  disc  diffusion-based  screening,  the  double
isc synergy  test  (DDST),  inhibitory  potentiated  disc
iffusion (IPDD)  and  E-strip  conﬁrmatory  tests.
As per  the  Clinical  and  Laboratory  Standards
nstitute (CLSI)  guidelines,  an  initial  screen  for
educed  susceptibility  to  more  than  one  of  the
ve indicator  cephalosporins  followed  by  a  conﬁr-
atory  test  can  improve  the  sensitivity  of  detec-
ion.  The  further  identiﬁcation  of  speciﬁc  genes
t
c
p
bssociated  with  the  production  of  ESBLs  can  be
erformed  using  speciﬁc  nucleic  acid-based  assays
8]. However,  these  molecular  assays  are  limited  to
esource-rich  settings  and  are  beyond  the  scope  of
outine microbiology  laboratories.
This study  aimed  to  identify  a suitable  pheno-
ypic method  for  the  detection  of  ESBL-producing
. coli  in  patients  with  symptomatic  UTI  cases  in  a
ertiary care  hospital  in  north-interior  Karnataka,
hich serves  a  rural  population  for  which  data
egarding the  incidence  of  ESBL-producing  strains
s lacking.
aterials and methods
his  prospective  study  was  conducted  in  the
epartment  of  Microbiology  at Navodaya  Medical
ollege  Hospital  and  Research  Centre,  Raichur,  Kar-
ataka, India.  A  total  of  750  consecutive  urine
amples from  patients  with  symptomatic  UTIs  were
creened.  Clean-catch  mid-stream  urine  samples
ere  collected  in  sterile  disposable  containers  (Uri-
ol, Hi-Media  Laboratories  Ltd.,  Mumbai,  India)
nd processed  within  1 h. A  semi-quantitative  loop
Hi-Media  Laboratories  Ltd.,  Mumbai,  India)  mea-
uring 2.2  mm  in  diameter  with  a  holding  capacity
f 0.005  mL  was  employed  to  culture  urine  on
lood  agar  and  MacConkey  agar.  The  inoculated
lates were  incubated  overnight  at  37 ◦C.  Iso-
ates present  at  a signiﬁcant  number  (colony  count
105 CFU/mL)  were  identiﬁed  according  to  stan-
ard procedures  [9].  Antibiotic  susceptibility  was
ested by  the  Kirby-Bauer  disc  diffusion  method  [10]
sing antibiotic  discs  containing  ampicillin  (10  g),
moxicillin/clavulanic  acid  (20/10  g),  trimetho-
rim/sulfamethoxazole  (1.25/23.75  g),  amikacin
30 g),  imipenem  (10  g),  gatiﬂoxacin  (5  g)  and
obramycin  (10  g).ion using  three  indicator  cephalosporins,  namely
eftazidime  (30  g),  cefotaxime  (30  g)  and  cef-
odoxime  (30  g).  The  isolates  were  considered  to
e resistant  if  the  diameter  of  the  inhibition  zone
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for  ceftazidime,  cefotaxime  or  cefpodoxime  was
≤22 mm,  ≤27  mm  or  ≤17  mm,  respectively.
The  strains  that  showed  resistance  to  at  least
one of  the  three  cephalosporins  were  tested  further
using phenotypic  conﬁrmation  methods  [10,11].
Double disc synergy test (DDST)
All  E.  coli  showing  resistance  to  any  of  the  three
indicator cephalosporins  were  tested  for  ESBL
production by  the  DDST.  Ceftazidime  (30  g),  cefo-
taxime  (30  g),  cefpodoxime  (30  g)  and  amoxi-
cillin/clavulanic  acid  (amoxicillin  20  g  +  clavulanic
acid 10  g)  (Hi-Media  Laboratories  Ltd.,  Mum-
bai, India)  were  used  for  ESBL  detection  [12,13].
Amoxicillin/clavulanic  acid  (20  g/10  g)  and  third-
generation  cephalosporin  discs  were  placed  at  a
distance of  20  mm  from  center  to  center  on  lawn
cultures  on  Muller—Hinton  agar  plates.  The  plates
were  incubated  at  37 ◦C  overnight.  Any  enhance-
ment in  zone  of  inhibition  of  cephalosporins
towards  the  amoxicillin/clavulanic  acid  disc  was
considered  a  positive  result  for  an  ESBL.
K. pneumoniae  ATCC  700603  and  E.  coli  ATCC
25922 were  used  as  controls.
Inhibitor potentiated disc diffusion test
(IPDD)
The  test  inoculum  was  matched  to  a 0.5  McFar-
land turbidity  standard  and  streaked  onto  two
Muller—Hinton  agar  plates,  one  supplemented  with
0.004 mg/L  potassium  clavulanate  (Sigma  Aldrich
Pvt. Ltd.,  Bangalore)  and  another  without  clavu-
lanate.  Ceftazidime  (30  g),  cefotaxime  (30  g)
and cefpodoxime  (30  g)  discs  were  placed  on  both
of these  plates.  The  agar  plates  were  then  incu-
bated  at  37 ◦C  overnight.  The  inhibition  zones  of
the discs  were  compared  between  the  plates  with
and without  clavulanate.  A  difference  of  ≥10  mm  in
the zone  diameter  was  considered  as  positive  result
for an  ESBL  [14,15].
ESBL E-strip test
The  ESBL  E-strip  test  (AB  BioMerieux,  Solna,
Sweden) is  based  on  two  gradients;  one  end
of the  strip  is  impregnated  with  ceftazidime
(0.5—32 g/mL),  and  the  opposite  end  is impreg-
nated with  ceftazidime  (0.125—8  g/mL)  and
clavulanate (4  g/mL).  The  test  was  performed  fol-
lowing the  manufacturer’s  instructions.  Brieﬂy,  an
overnight culture  of  the  test  organism  on  brain
heart infusion  agar  was  suspended  in  saline  to
match  the  turbidity  to  that  of  a  0.5  McFarland
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tandard.  This  suspension  was  then  used  to  inoc-
late a Muller  Hinton  agar  plate  by  swabbing  the
lates with  a sterile  cotton  swab.  After  drying,
he E-test  strip  was  placed  on  the  plate,  and
he plate  was  incubated  overnight  at  37 ◦C.  For
oth ends  of  the  strip,  the  point  of  intersection
etween the  inhibition  eclipse  and  the  edge  of  the
-test strip  was  considered  the  MIC.  According  to
he manufacturer,  a ceftazidime  MIC/ceftazidime-
lavulanate  MIC  ratio  ≥8  indicates  the  presence  of
SBL enzymes  [8,16].
tatistical analysis
he  results  were  analyzed  with  descriptive  statis-
ics wherever  appropriate.  The  Chi-square  test  was
sed to  evaluate  the  statistical  signiﬁcance  of  dif-
erences in  the  results.  A  p  value  of  <0.05  was
onsidered statistically  signiﬁcant.  Statistical  anal-
sis was  performed  using  SPSS  v16.0  software.
esult
 total  of  163  E.  coli  strains  were  isolated  in  sig-
iﬁcant  numbers  from  patients  with  symptomatic
TIs. These  strains  were  subjected  to  antibiotic  sus-
eptibility testing,  ESBL  screening  and  phenotype
onﬁrmation tests.
Antibiograms  revealed  that  153  (93.8%)  iso-
ates were  resistant  to  ampicillin,  62  (38%)  were
esistant  to  trimethoprim/sulfamethoxazole  and
1 (37.4%)  were  resistant  to  gatiﬂoxacin.  Resis-
ance to  tobramycin,  amoxicillin/clavulanate  and
mikacin was  noted  in  between  30%  and  19.6%  of
solates. Only  two  (1.2%)  strains  showed  resistance
o imipenem,  as  indicated  in  Table  1.
In a  disc-based  ESBL  screening  test,  80  (49%)
solates were  resistant  to  at  least  one  of  the
hree indicator  cephalosporins.  Resistance  was
ost frequently  observed  for  cefpodoxime  (n  =  75;
6.1%), followed  by  ceftazidime  (n  =  70;  43%)and
efotaxime (n  =  65;  39.9%).  Among  the  three
ephalosporins, ceftazidime  was  found  to  be  the
est antibiotic  for  the  ESBL  phenotypic  conﬁrma-
ory tests  when  using  either  the  DDST  or  the  IPDD
est, as  shown  in  Table  2.
The ESBL  E-strip  test  was  considered  the  gold
tandard, and  the  efﬁcacy  of  the  DDST  and  the  IPDD
est were  analyzed  in  comparison  with  the  E-strip
est. In  the  DDST,  15  (18.7%)  strains  were  positive
or ESBLs,  1  strain  gave  a false-positive  result,  and
3 (28.7%)  strains  gave  false-negative  results.  The
PDD test  gave  38  (47.5%)  ESBL  positives  with  a
10 mm  augmentation  of  the  inhibition  zone  diam-
ter. The  mean  zone  augmentation  (95%  conﬁdence
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Table  1  Comparison  of  resistance  pattern  between  ESBL  positives  and  negative  strains.
Pattern  Resistance
pattern  (n  =  163)
ESBL  positives
strains  (n  =  38)
ESBL  negative
strains  (n  =  125)
p  Value
Ampicillin  (A)  153  (93.8%)  38  (100%)  117  (93.6%)  0.19
Amoxyclav  (Ac) 38  (23.3%)  14  (36.8%)  24  (19.2%)  0.03
Cotrimoxazole  (Co) 62 (38.0%)  20 (52.6%)  42 (33.6%)  0.04
Amikacin  (Ak) 32 (19.6%)  13 (34.2%)  19 (15.2%)  <0.02
Imipenem  (I) 2 (1.2%)  2 (5.3%)  00
Gatiﬂoxacin  (Gf)  61  (37.4%)  21  (55.3%)  40  (32%)  0.01
Tobramycin  (Tb)  49  (30.0%)  16  (42.1%)  33  (26.4%)  0.07
ESBL  screening  indicators
Cefpodoxime(CEP)  75  (46.1%)  37  (97.3%)  38  (30.4%)  <0.0001
Ceftazidime  (CA)  70  (43.0%)  33  (86.8%)  37  (29.6%)  <0.0001
Cefotaxime  (CE)  65  (39.9%)  35  (92.1%)  30  (29.0%)  <0.0001
Table  2  Comparison  of  screening  and  conﬁrmatory  methods  for  the  detection  of  extended  spectrum  -lactamases.
Sl.  no  Cephalosporins  Screening  testa (n  =  163)  Conﬁrmatory  testsb (n  =  80)
DDST  IPDD  test  E-strip  test
1  Cefpodoxime  (CEP)  75  3  14  NA
2  Ceftazidime  (CA)  70  7  15  38
3  Cefotaxime  (CE)  65  5  09  NA
4  ESBL  positives  15  38  38
NA, not applicable.
a Disc diffusion test.
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nterval)  was  16.6  (13.1,  22.6)  mm  for  ceftazidime,
4.8 (12.4,  18.2)  mm  for  cefotaxime  and  19.2  (12.6,
8.4) mm  for  cefpodoxime,  as  shown  in  Table  3.
By the  ESBL  E-strip  test,  38  (47.5%)  strains
ere detected  as  ESBL  producers  with  a
eftazidime/ceftazidime-clavulanate  (TZ/TZL)
atio  between  8  and  256.  Of  the  38  ESBL-positive
trains, 34  had  a  TZ/TZL  ratio  of  between  32  and
56 and  a  MIC  log2 dilution  reduction  of  ≥5.  Four
trains (5.0%)  had  a  TZ/TZL  ratio  of  8 with  a MIC
og2 dilution  reduction  of  3—4.5.  The  remaining  42
52.5%) strains  were  ESBL  negative,  with  a  ratio  of
8 and  log2 reduction  of  <3,as  depicted  in  Table  4.
E
p
Table  3  Phenotypic  conﬁrmation  ESBLs  by  E-strip  test  and
No.  of  strains  Ceftazidime  MIC  
Alone  (TZ)  With  clavulanate  (TZL)
4 0.5 0.38—0.5 
5  0.5—2.0  0.25—0.75  
31  0.5—2.0  0.125—0.75  
6  1.5—2.0  0.19—0.25  
34  4.0—32.0  0.125—0.75  or antibiotic is selected for conﬁrmatory test.
Of  the  38  ESBL-positive  strains,  37  (97.3%)  were
esistant  to  cefpodoxime,  35  (92.1%)  were  resis-
ant to  cefotaxime  and  33  (86%)were  resistant  to
eftazidime.  Of  the  125  ESBL-negative  strains,  38
30.4%) were  resistant  to  cefpodoxime,  37  (29.6%)
ere resistant  to  ceftazidime  and  30  (29.0%)  were
esistant  to  cefotaxime.  Signiﬁcantly  more  ESBL-
ositive  strains  than  ESBL-negative  strains  were
esistant  to  amoxyclav,  cotrimoxazole,  amikacin
nd gatiﬂoxacin  (p  <  0.05).  Resistance  to  three  or
ore drugs  was  signiﬁcantly  more  common  in
SBL-producing  (97.3%)  strains  than  in  non-ESBL-
roducing (51.2%)  strains  (p  <  0.05)
 their  respective  log2 reduction.
TZ/TZL  ratio  MIC  log 2 reduction  %
1  0  5
2  1  6.2
3—4  2  38.7
6—8  3  7.5
32—256  ≥5  42.5
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Table  4  Phenotypic  conﬁrmation  of  screening  test  positive  ESBL  producers  by  Inhibitory  Potentiated  Disc  Diffusion
test.
Agents  Mean  zone  diameter  ±  SD  (mm)  Mean  zone  augmentation
(mm)  (95%  CI)
p Value
MH  agar  MH  agar  +  clavulanate
ESBL  positive  strains  (n  =  38)
Ceftazidime  18.6  ±  8.4  39.4  ±  5.2  16.6  (13.1,  22.6)  <0.001
Cefotaxime  22.7  ±  6.6  36.5  ±  4.1  14.8  (12.4,  18.2)  <0.001
Cefpodoxime 16.4  ±  4.9  35.2  ±  4.5  19.8  (12.4,  18.4)  <0.001
ESBL  negative  strains  (n  =  42)
Ceftazidime 37.2 ±  3.4  38.1 ±  2.6  1.4  (0.8,  2.4)  <0.001
Cefotaxime 34.5 ±  4.2  36.8 ±  2.1  1.6  (0.5,  2.6)  <0.001
Cefpodoxime 32.3  ±  2.4  35.2  ±  2.2  1.5  (0.6,2.0)  <0.001
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negative  strains.  ESBL  producers  exhibited  resis-CI, conﬁdence interval; MH, Muller Hinton.
Discussion
In  the  present  study,  80  (49%)  E.  coli  strains
from patients  with  symptomatic  UTIs  exhibited
resistance to  at  least  one  of  the  three  indica-
tor cephalosporins.  Of  these  80  strains,  38  (23.3%)
were  identiﬁed  as  ESBL  producers  by  the  IPDD  and
the E-strip  tests.  However,  only15  (18.7%)  strains
tested  positive  according  to  the  DDST.  Kumar  et  al.
[17] identiﬁed  19.8%  of  Enterobacteriaceae  iso-
lates as  potential  ESBL  producers  by  the  DDST,
with 63.7%  of  E.  coli  isolates  and  14%  of  K.  pneu-
moniae isolates  exhibiting  ESBL  production.  In  a
previous study  in  Western  India,  48.3%  of  urinary
isolates resistant  to  cefotaxime  were  ESBL  produc-
ers [18].
The  IPDD  test  appeared  to  be  a  better  method
than the  DDST  for  conﬁrming  ESBL  production,
showing a  sensitivity  and  speciﬁcity  of  100%  and
97.6%,  respectively.  The  DDST  failed  to  detect
28.7% of  ESBL  producers,  with  a  sensitivity  of  39.4%
and a  positive  predictive  value  of  93.7%.  The  sensi-
tivity of  the  DDST  strongly  depends  on  the  precise
placement  of  the  discs  [14].  Previous  studies  have
found that  the  E-strip  test  method  is  sensitive,  reli-
able and  convenient  [16];  thus,  this  test  was  used
as the  gold  standard  for  identifying  ESBL  producers
in our  study.
All cephalosporins  used  in  the  IPDD  test  showed
increased inhibition  zone  diameters  (≥10  mm)  for
ESBL producers.  Cefpodoxime  had  a  greater  mean
zone augmentation  (19.2  mm)  than  ceftazidime
(16.6 mm)  and  cefotaxime  (14.8  mm).  Our  results
are in  complete  agreement  with  the  previous  ﬁnd-
ings of  Ho  et  al.  [14]  that  the  IPDD  test  is  more
sensitive when  ceftazidime  is  used  than  when  cefo-
taxime is  used.  The  advantage  of  the  IPDD  test
is that  ESBL  producers  can  be  clearly  differenti-
ated from  non-producers  using  a  cut-off  of  ≥10  mm
t
a
wor  the  zone  augmentation  and  three  oxyimino-
ephalosporins can  be  tested  on  one  agar  plate.
Ceftazidime is  considered  an  excellent  substrate
or most  ESBL  enzymes  [19,20],  and  Bush  group
be enzymes  can  be  differentiated  from  other
-lactamase enzymes  (chromosomal  or  chromoso-
ally derived  AmpC  enzymes)  by  the  reduction
n the  ceftazidime  MIC  in  the  presence  of  some
linically useful  -lactamase  inhibitors  such  as
lavulanate  [21].  Sanders  et  al.  [22]  suggested  that
he Vitek  ESBL  test  and  the  E-strip  test  are  more
ensitive  than  the  disc  approximation  test  for  the
etection of  Bush  group  2be  enzymes.
One drawback  of  these  phenotypic  methods  is
hat inhibitor-resistant  -lactamases  might  not  be
etected. The  ESBL  conﬁrmatory  test  is  based  on
he demonstration  of  inhibition  by  clavulanate.
owever, other  -lactam  resistance  factors,  includ-
ng AmpC-type  enzymes,  porin  changes  and  variants
f the  original  ESBL  enzymes,  may  be  co-exist  with
SBLs, interfering  with  the  results  of  these  tests.
The need  for  a two-step  strategy  (screening  and
onﬁrmatory  tests)  due  to  the  presence  of  a  high
umber  of  false  positives  in  the  initial  screening
ay result  in  increased  turnaround  time  and  costs
or the  laboratory.  Furthermore,  the  sensitivity  of
he DDST  strongly  depends  on  the  precise  place-
ent of  the  discs  and  the  interpretation  of  the  DDST
esults is  more  subjective  than  the  interpretation  of
he E-strip  and  IPDD  results.  Thus,  IPDD  test  may  be
referred because  it  is  equally  sensitive  to  the  E-
trip test  but  less  expensive,  and  a single  plate  can
e used  to  test  more  than  one  cephalosporin.
The  antibiotic  resistance  of  ESBL-positive  strains
as signiﬁcantly  higher  (p  <  0.05)  than  that  of  ESBL-ance to  trimethoprim/sulfamethoxazole  (52.6%)
nd amikacin  (34.2%).  A  similar  resistance  pattern
as observed  in  other  studies  [23—25].  Resistance
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[
[etection  of  ESBL  in  patients  with  urinary  tract  infe
o  third-generation  cephalosporins  was  found  to
o-exist with  resistance  to  ﬂuoroquinolones  and
minoglycosides,  consistent  with  the  reports  of
ubha and  Ananthan  [26]  and  Dutta  Roy  et  al.  [12].
e also  observed  that  most  ESBL  producers  (97.3%)
ere  resistant  to  two  or  more  drugs,  whereas  only
1.2% of  non-ESBL  producers  were  multidrug  resis-
ant. This  ﬁnding  is  in  agreement  with  the  results  of
 study  by  Tankhiwale  et  al.,  who  reported  that  mul-
idrug resistance  was  signiﬁcantly  more  common  in
SBL producers  than  in  non-producers  [18].
In our  region,  phenotypic  data  regarding  ESBL
ccurrence  are  lacking.  Further  studies  including
ore isolates  and  using  genotypic  methods  for  con-
rmation  are  required  to  validate  the  above  results.
n infections  with  ESBL-producing  strains,  slight
ncrease  in  the  MICs  of  oxyimino-cephalosporins
as been  reported  to  be  sufﬁcient  to  cause  treat-
ent failure.  Over  reliance  on  third-generation
ephalosporins  to  treat  gram-negative  infections
s one  of  the  primary  factors  responsible  for  the
ncreased  resistance  to  this  class  of  antibiotics,
nd most  of  the  ESBL-producing  strains  included
n this  study  were  multidrug  resistant.  The  accu-
ate detection  and  reporting  of  ESBL  production  by
linical isolates  are  therefore  crucial.  The  moni-
oring  and  judicious  usage  of  extended-spectrum
ephalosporins,  periodic  surveillance  of  antibiotic
esistance  patterns  and  efforts  to  decrease  empir-
cal antibiotic  therapy  would  be  greatly  effective
n addressing  some  of  the  problems  associated  with
SBLs.
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